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Background: Biomarkers based on the underlying pathology of Alzheimer’s disease (AD) and Dementia with Lewy
Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in
these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in
patients with AD, DLB and Parkinson’s disease (PD) using the amyloid imaging agent florbetapir F 18 and 18F-AV-133
(florbenazine), a marker for vesicular monamine type 2 transporters (VMAT2).
Methods: Patients with DLB and AD, Parkinson’s disease (PD) and healthy controls (HC) were recruited for this study.
On separate days, subjects received intravenous injections of florbetapir, and florbenazine. Amyloid burden and VMAT2
density were assessed quantitatively and by binary clinical interpretation. Imaging results for both tracers were
compared across the four individual diagnostic groups and for combined groups based on underlying pathology
(AD/DLB vs. PD/HC for amyloid burden and PD/DLB vs. AD/HC for VMAT binding) and correlated with measures of
cognition and parkinsonism.
Results: 11 DLB, 10 AD, 5 PD, and 5 controls participated in the study. Amyloid binding was significantly higher in the
combined AD/DLB patient group (n = 21) compared to the PD/HC groups (n = 10, mean SUVr: 1.42 vs. 1.07; p = 0.0006).
VMAT2 density was significantly lower in the PD/DLB group (n = 16) compared to the AD/ HC group (n = 15; 1.83 vs. 2.97;
p < 0.0001). Within the DLB group, there was a significant correlation between cognitive performance and striatal
florbenazine binding (r = 0.73; p = 0.011).
Conclusions: The results of this study show significant differences in both florbetapir and florbenazine imaging that are
consistent with expected pathology. In addition, VMAT density correlated significantly with cognitive impairment in DLB
patients (ClinicalTrials.gov identifier: NCT00857506, registered March 5, 2009).
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Alzheimer’s disease (AD) is the most frequent cause of
dementia in the US, and is responsible for up to 70% of
cases [1]. Dementia with Lewy Bodies (DLB) is the sec-
ond most common degenerative dementia, accounting
for approximately 15%-30% of cases at autopsy [2].
Based on clinical features, diagnostic criteria have been* Correspondence: marwan.sabbagh@bannerhealth.com
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unless otherwise stated.developed to differentiate DLB from AD [2,3]. While
these criteria improve classification, there is still consid-
erable misdiagnosis compared to autopsy, particularly
early in the disease course [4,5]. More accurate differen-
tiation of these two conditions could provide clinically
relevant prognostic information [6,7] and influence
treatment decisions [8-10].
Biomarkers based on the underlying pathology of AD
and DLB have the potential to improve diagnosis 11C-la-
beled Pittsburgh compound B (11C-PiB) was the firstal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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patients [11]. The PET tracer florbetapir F 18 (Amyvid)
differs from PiB as it has a longer half-life (109 min versus
20 min). Florbetapir PET correlates with beta-amyloid
pathology at post-mortem [12]. PET and/or SPECT li-
gands that assess the integrity of the dopamine system
have been available for several decades as indirect mea-
sures of dopaminergic neurodegeneration [13]. Florbena-
zine (AV-133) is a fluorinated VMAT-2 ligand for PET
that has been shown to identify dopaminergic deficits in
patients with PD and DLB [14,15].
The purpose of this study was to determine whether
florbetapir PET would detect amyloid deposition in AD
and DLB patients, and whether florbenazine PET would
identify decreased VMAT2 density in PD and DLB pa-
tients. Secondary goals were to determine the reliability of
expert interpretation in a cohort with a mixture of neuro-
degenerative disorders and to further assess the safety and
tolerability of florbetapir and florbenazine. This informa-
tion would help determine whether the combination of
florbetapir and florbenazine merit further investigation as
a potential adjunct to clinical evaluation in the diagnosis
of patients with dementia.
Methods
Study design
This study (AV133-B03 (ClinicalTrials.gov identifier:
NCT00857506) was sponsored by Avid Radiopharmaceuti-
cals (a subsidiary of Eli Lilly and Co.). The study was ap-
proved by the Institutional Review Boards (IRB) at the
University of Pennsylvania, University of California at San
Diego and Banner Sun Health Research Institute. Written
informed consent was obtained from study participants
and/or their authorized representatives prior to conduct of
any study procedures. The study consisted of a screening
visit and two imaging visits. Screening assessments in-
cluded demographic information, safety assessment, in-
cluding clinical laboratory assessment, vital signs and ECG,
and an MRI scan. Each subject was imaged on 2 separate
sessions not more than 4 weeks apart.
Research participants
All subjects were >50 years of age and had to be able to toler-
ate two PET imaging sessions. AD and DLB subjects had to
have a caregiver who could report on their mental status and
activities of daily living. DLB subjects were enrolled if they met
the diagnostic criteria for probable DLB [2] and did not meet
the National Institute of Neurological and Communicative
Disorders and Stroke and Alzheimer’s disease and Related Dis-
orders Association (NINCDS-ADRDA) criteria for probable
AD [16]. AD subjects were enrolled if they met the NINCDS
criteria for probable AD, had a Mini Mental State Examin-
ation (MMSE) [17] score at screening between 10 and 24
inclusive and had no symptoms of parkinsonism. PDsubjects were defined by research diagnostic criteria for
probable PD [18] and did not have cognitive impairment
based on the judgment of the enrolling investigator. HC
subject were enrolled if they were cognitively normal and
had no evidence of parkinsonism.
Patient groups were combined for some analyses. For
analyses of florbetapir PET, the combined AD and DLB
groups were compared to the combined PD and HC
groups testing the hypothesis that AD and DLB patients
would typically be amyloid positive (Aβ + PET scans)
whereas PD and HC subjects would be, in general, amyl-
oid negative (Aβ-). For analysis of florbenazine PET the
combined PD and DLB groups were compared to the
combined AD and HC groups.
Clinical assessments
Demographic information including age, gender, educa-
tion and disease duration (for patient groups) was col-
lected for all subjects. Motor function was assessed using
part III of the Unified Parkinson Disease Rating Scale
(UPDRS) [19]. Motor examinations were performed in the
practically defined “off” state, at least 12 hours after the
last dose, in subjects receiving dopaminergic treatment
[20]. Cognitive performance was rated with the MMSE.
Non-serious adverse experiences were recorded for
24 hours after imaging and serious adverse experiences
were collected for up to 30 days post-imaging.
Scan acquisition
Subjects underwent a 10 minute acquisition (1×10 frame
or 2×5 minutes frames), 50 minutes after intravenous in-
jection of 10 mCi (370 MBq) of florbetapir F 18. For the
florbenazine imaging session, an i.v. bolus of 5 mCi
(185 MBq) of 18 F-AV-133 was administered. Brain scans
were acquired over an approximately 10 min period,
50 minutes after injection. For both tracers, data was ac-
quired from 3 sites, including 2 PET/CT scanners: Bio-
graph 2 slice PET/CT and Biograph mCT 40 slice PET/
CT and a dedicated PET scanner (ECAT HR+) all manu-
factured by Siemens Medical Solutions, Knoxville, TN. Im-
ages were reconstructed using iterative reconstruction. No
post-reconstruction technique, such as smoothing or par-
tial volume correction, was applied to the images.
Image analysis
Five experienced nuclear medicine physicians independ-
ently reviewed all PET images. Readers had been trained to
read both scans in a standardized fashion, and were blinded
to clinical data. The interpretation given by the majority of
the five readers’ for each image was used for analysis. Flor-
betapir scans were interpreted qualitatively and quantita-
tively as described previously [12,21,22]. For florbenazine,
the readers conducted a binary assessment identifying the
presence or absence of dopaminergic degeneration based
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the striatum. Florbenazine images were spatially normal-
ized to a standard atlas using a AV-133 PET template.
Atlas-based volumes of interest (VOIs) were applied for
target areas (caudate, anterior and posterior putamen and
total striatum) and for the occipital cortex reference re-
gion. The ratio of tracer activity in target VOIs relative to
the occipital cortex as a reference region was calculated to
create standard uptake value ratios (SUVr).
Statistical methods
The differences among diagnostic groups in the propor-
tion of positive scans either for amyloid or dopamine de-
ficiency was assessed with Fisher’s exact test. Kruskall-
Wallis test was used to compare the mean SUVr values
across diagnostic groups and for the combined groups
(eg. AD and DLB). If the Kruskall-Wallis test detected a
significant overall difference, then Wilcoxon rank sum
test was applied to compare the following groups: DLB
vs. AD, DLB vs. HC, PD vs. AD, PD vs. HC. Linear re-
gression was used to explore the relationship between
measures of motor and cognitive performance and im-
aging data. Receiver operator characteristic (ROC) ana-
lysis was used to test the discrimination between groups.
The optimal cut-off point was identified using Youden
Index method. Fleiss’ kappa was calculated for both im-
aging modalities to assess inter-rater reliability [23].
Results
Demographic features
The study included 11 subjects clinically diagnosed with
DLB, 10 with AD, 5 with PD, and 5 HC subjects (Table 1).
The mean age did not differ significantly among the 4
groups. The gender distribution varied by group, with a
higher proportion of men in the Lewy body disorders group
(PD and DLB) compared to AD and HC (p = 0.0558). Over
80% of participants had at least a college education. The
combined PD and DLB group demonstrated greater de-
grees of parkinsonism with higher mean scores on the
UPDRS compared to AD and controls (51.81 vs. 13.07; p <Table 1 Demographics characteristics by clinical diagnosis
HC P
(N = 5) (
Age 66.40 (11.67) 6
% female 100 2
Education (number of years. high school = 12, college = 16) 16.40 (0.89) 1
Disease duration** mean (range) NA 1
MMSE; mean (SD) 29.60 (0.55) 2
UPDRS; mean (SD) 1.40 (2.61) 3
MMSE =mini-mental status examination; UPDRS = Unified Parkinson Disease Rating
*Letters indicate pairwise comparisons significant at p < 0.05; a = HC vs. PD; b = HC
**Years since diagnosis.0.0001). The combined AD and DLB group had greater
cognitive impairment than the PD and control group
(19.19 vs. 29.70, respectively; p < 0.0001). The mean MMSE
score for the DLB group was 18.36 (sd 8.94), and the mean
MMSE score for the AD group was 20.1 (sd 3.57).
Florbetapir and florbenazine binding
Mean cortical florbetapir SUVr values were highest in
the AD group (SUVr =1.53; sd 0.184), followed by the
DLB group (1.32; sd 0.285; Table 2). As hypothesized,
the mean florbetapir SUVr was higher in the combined
AD and DLB group than in the combined PD and HC
group (1.42 vs. 1.07; p = 0.0006).
Mean striatal florbenazine binding was lowest (most
abnormal) in the PD group (SUVr = 1.72; sd = 0.172),
followed by the DLB group (SUVr = 1.87; sd = 0.372).
Mean striatal florbenazine binding in AD subjects was
similar to controls (3.04; sd 0.579 and 2.84; sd 0.552, re-
spectively). There were significant group differences in
mean striatal SUVr for the combined PD and DLB group
compared to the combined AD and control group (1.83
vs. 2.97; p < 0.0001). Among striatal sub-regions, the
greatest difference between groups was observed for the
lowest posterior putamen (Table 3).
There were some cases of overlap in florbetapir
SUVr values between patients in the 4 diagnostic
groups (Figure 1a). All AD cases and 7/11 DLB cases
had mean cortical florbetapir SUVr values greater than
the published cut-off of 1.1 SUVr units [12]. 4/5 con-
trols and 3/5 PD patients were below this cut-off. The
area under the ROC curve for florbetapir mean cortical
SUVr for the comparison between the combined AD and
DLB group and the combined PD and control group was
0.855 (p < 0.0001). There was less overlap for florbenazine
between combined PD and DLB subjects compared to
combined AD subjects and controls (Figure 1b). For this
contrast, ROC analysis using the posterior putamen region
showed an AUC of 0.996 (p = <0.0001). The florbenazine
SUVr cut-off for the posterior putamen region that pro-
vided the best balance of sensitivity and specificity for PD/D AD DLB P-value Pair-wise
comparison*N = 5) (n = 10) (n = 11)
8.20 (7.76) 75.70 (9.46) 70.18 (9.02) 0.2333
0 50 36.36 0.0558 a,c
7.20 (1.10) 15.40 (2.50) 15.09 (3.15) 0.4252
.94 (0.93-2.75) 2.08 (0.35-4.47) 1.98 (0.74-3.65) 0.9944
9.80 (0.45) 20.10 (3.57) 18.36 (8.94) 0.0002 b,c,d,e
0.60 (9.74) 18.90 (20.72) 61.46 (20.54) <0.0001 a,b,c,d,e,f
Scalep-value from Kruskal-Wallis test and Fisher exact test.
vs. AD; c = HC vs. DLB; d = PD vs. AD; e = PD vs. DLB; f = AD vs. DLB.
Table 2 Florbetapir SUVr for selected cortical regions by diagnostic group
HC PD AD DLB P value Pair-wise comparison*
Average of cortical regions 1.02 (0.096) 1.12 (0.249) 1.53 (0.184) 1.32 (0.285) 0.0047 b,d
Frontal cortex 0.91 (0.046) 0.98 (0.219) 1.34 (0.204) 1.15 (0.285) 0.0059 b,d
Temporal cortex 1.06 (0.080) 1.11 (0.197) 1.57 (0.191) 1.37 (0.283) 0.0030 b,d
Parietal cortex 0.98 (0.097) 1.01 (0.335) 1.42 (0.188) 1.21 (0.235) 0.0111 b,f
Anterior cingulate 1.00 (0.087) 1.14 (0.241) 1.62 (0.245) 1.32 (0.345) 0.0038 b,d,f
Posterior cingulate 1.03 (0.125) 1.14 (0.312) 1.47 (0.212) 1.38 (0.300) 0.0131 b,c,d
Precuneus 1.16 (0.192) 1.30 (0.302) 1.77 (0.219) 1.51 (0.353) 0.0057 b,d
*a = HC vs. PD; b = HC vs. AD; c = HC vs. DLB; d = PD vs. AD; e = PD vs. DLB; f = AD vs. DLB.
Mean SUVr values (and SD) are given for each group. P-values are for the overall group comparison from Kruskal-Wallis test. Subsequent pair-wise comparisons
are noted by the letters in the last column if the overall comparison was significant at p < 0.05.
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sulted in sensitivity of 88% (95% CI: 64%-97%) and specifi-
city of 100% (95% CI: 70%-100%).
Binary clinical interpretation
The clinical reading for the florbetapir scan was positive
in 9 of 10 cases in the AD group and 7/11 cases in the
DLB group. It was negative in 4/5 PD patients and all
HCs. Overall, the florbetapir qualitative reading was
positive in 17/20 cases when the mean cortical SUVr
was above 1.1 SUVr units and negative 11/11 cases
where the mean cortical SUVr was at or below 1.1 SUVr
units, or over 90% correspondence to the published cut-
off. For florbenazine, the majority clinical reading was
positive for dopamine degeneration in all PD cases and
8/11 DLB case, and negative in all AD cases and HCs.
The posterior putamen SUVr cut-off that produced the
best agreement with visual interpretation for was 2.12,
which is lower than the cut-off that produced the great-
est balance of sensitivity and specificity for differentiat-
ing between clinical groups (SUVr = 2.3).
Fleiss’ kappa for the binary interpretation among the 5
expert raters was 0.88 (95% CI 0.77-0.99) for florbetapirTable 3 Florbenazine SUVR by Clinical Diagnosis for each stri
HC PD AD
Whole striatum* 2.84 (0.552) 1.72 (0.172) 3.04
Caudate 2.60(0.529) 1.77 (0.415) 2.21
Anterior putamen 2.98 (0.601) 1.86 (0.084) 3.39
Posterior putamen 2.93 (0.529) 1.53 (0.104) 3.52
Lower posterior putamen** 2.82 (0.474) 1.46 (0.120) 3.41
Laterality index*** 0.94 (0.029) 0.91 (0.043) 0.94
Caudate/putamen ratio**** 0.88 (0.035) 1.15 (0.240) 0.64
*Average of left and right caudate, anterior putamen and posterior putamen.
**Posterior putamen with lower SUVr for each subject.
***Ratio of lower to higher posterior putamen for each subject. A higher value indic
****Ratio of average caudate (left and right) to average posterior putamen (left and
posterior putamen.
Mean SUVr values (and SD) are given for each group. P-values are for the overall gr
are noted by the letters in the last column if the overall comparison was significant
e = PD vs. DLB; f = AD vs. DLB).and 0.95 (95% CI 0.84-1.00) for florbenazine. When the
analysis is confined to only demented subjects (AD and
DLB, n = 21), Fleiss kappa was 0.90 (95% CI 0.77-1.00)
for florbetapir and was 0.92 (95% CI 0.78-1.00) for
florbenazine.
Combined amyloid and dopamine imaging
Based on majority binary visual interpretations, four pat-
terns of scan results were possible: AB+/DD+; AB+/DD-;
AB-/DD+; AB-/DD-. There were significant differences be-
tween groups in the frequency of these patterns (p < 0.001).
9 out of 10 subjects with AD had a florbetapir scan read as
positive and a florbenazine scan read as negative , 5/5 con-
trols were negative on both scans. 4/5 PD patients had nor-
mal florbetapir imaging and abnormal florbenazine scans.
By contrast, the DLB group had heterogeneous imaging re-
sults: 5/11 were abnormal on both measures; 3/11 had ab-
normal florbenazine and normal florbetapir; 2/11 had
normal florbenazine and abnormal florbetapir and 1 case
was normal on both measures. There were also significant
differences between groups in the pattern of amyloid and
dopamine abnormalities using quantitative analysis rather
visual interpretation (p < 0.001; Figure 2).atal region
DLB P value Pair-wise comparison
(0.579) 1.87 (0.372) 0.0001 a, c, d, f
(0.458) 1.79 (0.418) 0.0303 c, f
(0.744) 2.05 (0.519) 0.0003 a, c, d, f
(0.758) 1.78 (0.400) <0.0001 a, c, d, f
(0.753) 1.67 (0.427) <0.0001 a, c, d, f
(0.032) 0.88 (0.105) 0.5582
(0.151) 1.03 (0.240) 0.0011 b, d, f
ates greater asymmetry.
right). A higher value indicates greater difference between the caudate and
oup comparison from Kruskal-Wallis test. Subsequent pair-wise comparisons
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Figure 1 Scatterplots showing a) average cortical florbetapir SUVr values for each group and b) florbenazine binding for the lowest
posterior putamen region for each group. See text for description of discrimination between groups.
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We did not find a significant correlation between severity
of parkinsonism and florbenazine binding in either the PD
or DLB groups (data not shown). Likewise, there was no
significant correlation between florbetapir binding and cog-
nition in the PD, AD or HC groups. However, within the
DLB group, cases with a positive florbetapir scan based on
binary clinical interpretation had significantly lower MMSE
scores (14.4 vs. 25.3; p = 0.046), and there was a trend to-
ward a significant correlation between MMSE score and
mean cortical florbetapir SUVr in this group (r = −0.54; p =
0.0842). There was a significant association between mean
striatal florbenazine binding and MMSE in the DLB group
(r = 0.73; p = 0.011). The striatal sub-region that had
the strongest association with MMSE was with the caudate(r = 0.72; p = 0.012), while the correlation between MMSE
and the posterior putamen was not significant (r = 0.39; p =
0.242). When considering the two biomarkers together, a
model containing caudate florbenazine SUVr and mean
cortical florbetapir SUVr explained 56% of the variance in
MMSE in the DLB group (adjusted R2 = 0.559, p = 0.0156,
for model fit).
Safety results
There were no treatment-related adverse events. One sub-
ject died 5 days after florbenazine PET. The subject had
been in hospice, and the study investigator judged that the
death was unlikely to be study-related. In addition, 3 sub-
jects experienced at least 1 treatment emergent AE, none




























1 2 3 4 5
Posterior putamen florbenazine SUVr
Controls Dementia with Lewy Bodies
Parkinson's Disease Alzheimer's Disease
Figure 2 Pattern of scan results for florbetapir and florbenazine for subjects in the 4 diagnostic groups. The vertical line shows the
florbenazine SUVr cut-off (2.12) that agrees best with expert visual interpretation. The horizontal line (SUVr = 1.1) marks the published quantitative
cut-off for florbetapir. The distribution of imaging patterns (proportion of subjects in each quadrant) differed significantly between groups (chi2 =
41.7, p <0.001) In the AD, PD and HC groups, there was one dominant pattern (for example, all of the AD cases had positive florbetapir scans and
negative florbenazine scans). While VMAT2 binding was low in the DLB group on average, three subjects had SUVr values above the cut-off, and
no single imaging pattern was observed in a majority of DLB patient.
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ject in the AD group had a patella fracture related to a fall.
Discussion
We found significantly greater amyloid deposition in pa-
tients with AD or DLB compared to PD patients or con-
trols. We also found significant reductions in VMAT
density in PD and DLB patients compared to AD patients
or controls. In addition, there was significant inter-rater
reliability for both florbetapir and florbenazine.
A characteristic pattern of amyloid and dopamine im-
aging was present in nearly all subjects with PD and AD.
These results are consistent with prior studies in which the
frequency of amyloid deposition in PD is similar to age-
matched asymptomatic individuals in the general popula-
tion [24-27]. We found no cases with a clinical diagnosis of
AD with abnormal florbenazine imaging. Other studies
have reported similarly high specificity (90-97%) for dopa-
minergic imaging for the detection of DLB vs. AD [28,29].
Our finding of heterogeneous imaging results in DLB
patients is also consistent with the existing literature. An-
other study that found 4/14 cases with clinical DLB had
normal dopaminergic imaging, and two of these cases had
normal amyloid imaging, as well [30]. In the absence of
autopsy confirmation, the discrepancy between clinical
diagnosis and imaging cannot be fully resolved. Clinical
misdiagnosis may be the most likely explanation. Autopsy
studies show that up to 50% of cases clinically diagnosed
with DLB in life actually have AD [31]. One imaging study
with autopsy follow-up showed that 7/8 cases with aclinical diagnosis of DLB and normal dopaminergic im-
aging had a diagnosis of AD at autopsy [32]. Nonetheless,
the possibility of correctly diagnosed DLB with a normal
florbenazine PET scan cannot be entirely excluded. Ab-
sence of substantial nigra cell loss is observed in approxi-
mately 10% of DLB cases at autopsy [33]. An imaging
study with autopsy follow-up found 7 clinical DLB cases
with normal dopamine transporter SPECT imaging. Two
of these cases had DLB at autopsy (while the remainder
had AD). These 2 cases had preserved cell counts in the
substantia nigra in spite of the presence of synuclein
pathology [34]. Thus, dopaminergic imaging may be
normal in DLB cases with synuclein pathology but with-
out extensive nigral degeneration.
Within the DLB group, increasing cognitive dysfunction
was associated with decreased VMAT density and greater
amyloid deposition. While a link between cognitive dys-
function and dopaminergic denervation has not been con-
sistently reported for DLB, dopaminergic abnormalities
have been associated with the presence of neuropsychi-
atric features in DLB. [35] In addition, an association be-
tween dopaminergic imaging abnormalities and worse
cognitive performance in PD with dementia (PDD) pa-
tients has been reported [36,37]. In longitudinal studies,
both amyloid deposition and dopamine deficiency have
been associated with the risk of cognitive decline in pa-
tients with PD. [38,39] Our study may have been particu-
larly suited to identify an association between cognition
and florbenazine imaging because of the large variance in
both of these parameters in the DLB patients. For
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4–28. Larger studies with more detailed cognitive testing
and longitudinal follow up are needed to confirm our find-
ings. It is possible that dopamine and/or amyloid imaging
could identify clinically and biologically relevant sub-
groups of DLB patients.
There was significant inter-rater reliability for both flor-
betapir and florbenazine. In each case, the reliability would
be considered excellent based on the standards proposed
by Landis and Koch although the number of cases inter-
preted were small [40]. There was also agreement of the
florbetapir majority read with the published cut-off for flor-
betapir [12]. Prior studies [12,22] have demonstrated signifi-
cant reliability for florbetapir in cohorts consisting of cases
of established AD, age-matched controls and young,
healthy volunteers. Our results extend these findings to a
cohort with a mix of neurodegenerative disorders.
This study needs to be considered in light of several
limitations, particularly a small sample size and limited
clinical assessments. It is possible that we may have ob-
served more specific effects on cognition if more de-
tailed testing was performed. Second, even though
motor testing with the UPDRS was done while patients
had not taken their regular medications, the effects of
treatment may not have been completely washed out.
This factor may partially explain why we did not find a
statistically significant relationship between parkinson-
ism and VMAT density in either the PD or DLB groups.
Finally, there is no autopsy confirmation of the diagno-
sis of our subjects. Autopsy diagnosis is particularly im-
portant in DLB where there is substantial clinical,
biomarker and pathological heterogeneity.
The results of this study suggest several areas of fu-
ture investigation. Given the very small number of sub-
jects included per group, these are only preliminary
findings. A larger series, possibly with post-mortem
diagnostic confirmation, will be required to confirm the
findings. Larger studies could further evaluate the po-
tential of combined amyloid and dopamine imaging in
differentiating AD and DLB. In the case of DLB, studies
in independent cohorts could confirm our finding that
the degree of dopaminergic degeneration correlates
with greater cognitive impairment. Importantly, the
presence of co-existing amyloid may identify a subset of
DLB patients with distinct pathology who may have dif-
ferent prognosis or who might be candidates for treat-
ment trials of anti-amyloid therapies.
Conclusions
The results of this study show that the combination of
dopaminergic and amyloid imaging has the potential to
identify distinct biomarker signatures among patients
with PD, DLB and AD. In particular, there appears to be
heterogeneity in the biomarker abnormalities observed inpatients with a clinical diagnosis of DLB. These findings
may have implications for the prognosis and treatment of
patients with these disorders.Competing interests
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